Advanced Cell Technology Inc. is a biotechnology company applying cellular technology in the field of regenerative medicine. They apply stem cell-based technologies and other proprietary methods in the field of regenerative medicine to bring patient-specific therapies from the lab to the bedside. ACTC has their headquarters in Santa Monica, California, and they have a laboratory facility in Marlborough, Massachusetts.
The Company has three cellular product platforms based on innovative stem cell technology. They are focusing on commercializing their Retinal Pigment Epithelial (RPE) therapy for degenerative retinal disease. The Company has recently initiated two Phase 1/2 clinical trials. They are also focusing on their Phase II-approved Myoblast stem cell therapy for the treatment of chronic heart failure, advanced cardiac disease, myocardial infarction, and ischemia. In addition, the Company is developing their human embryonic stem cell (hESC)-based Hemangioblast (HG) platform for the treatment of blood and cardiovascular diseases. They are developing this program in partnership with CHA Biotech of Korea.
ACTC owns or licenses over 150 patents and patent applications related to stem cell therapy and regenerative medicine. They secured a patent on their “embryo-safe” single-blastomere technology. They also secured a broad patent for production of RPE cells. Their RPE and HG programs are human embryonic stem cell (hESC)-based. Their Phase II-approved Myoblast program for cardiac disease is an autologous adult stem cell therapy.
Last week, ACTC announced that the independent Data and Safety Monitoring Board (DSMB) overseeing the Company’s two ongoing stem cell clinical trials in the United States authorized ACTC to move forward with enrolling and treating the next set of patients in each of the trials. In July, surgeons led by Steven Schwartz, M.D., Ahmanson Professor of Ophthalmology at the David Geffen School of Medicine at UCLA and retina division chief at UCLA’s Jules Stein Eye Institute treated the first patients in the Company’s clinical trials for Stargardt’s Macular Dystrophy (SMD) and Dry Age-Related Macular Degeneration (Dry AMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs).
In addition, the Company recently received approval for a stem cell trial in Europe. They received clearance from the U.K. Medicines and Healthcare products Regulatory Agency to begin treating patients as part of a Phase 1/2 clinical trial for Stargardt’s Macular Dystrophy (SMD) using retinal pigment epithelium derived from human embryonic stem cells. The European Medicines Agency previously granted Orphan Drug designation for the Company’s RPE cell product for use in treating SMD.
About QualityStocks:
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://Gotstocks.QualityStocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment